モノジェニックまたはシンドロミックな肥満の成人のセトメラノチドの実用的な有効性と安全性:前向きなコホート研究
Francois Mifsud1, Sarah Chalopin1, Emilie Guillon1,2
1Assistance Publique Hôpitaux de Paris, Service de Nutrition, Centre Référent PRADORT "Syndrome de Prader-Willi et Autres Obésités Rares Avec Troubles du Comportement Alimentaire," Hôpital Pitié-Salpêtrière, Paris, France.
Obesity (Silver Spring, Md.)
|September 2, 2025
まとめ
セトメラノチドは,希少な遺伝的肥満の患者の体重を効果的に減らし,食生活を改善し,その長期的な安全性と臨床的効果を現実環境で確認しました.
科学分野:
- 内分泌学
- 遺伝学
- 薬理学について
背景:
- セトメラノチドはメラノコルチン-4受容体 (MC4R) 経路を標的とする.
- LEPR,POMC変種,Bardet-Biedl症候群 (BBS) に起因する単一性肥満は珍しい遺伝疾患である.
- 臨床試験ではセトメラノチドの有効性が示されていますが,実際のデータは限られています.
研究 の 目的:
- セトメラノチドの長期的効果と安全性を評価する.
- 珍しい遺伝的肥満患者の体重,食生活,および安全性に対するセトメラノチドの影響を評価する.
- 早期アクセス許可の下で治療を受けている患者の証拠を提供すること.
主な方法:
- BBS,LEPR,またはPOMCの変種による肥満患者17人を対象とした前向きな単心コホート研究.
- 患者は,通常の治療または臨床試験後の継続治療でセットメラノチドを投与された.
- 平均追跡期間は14. 4ヶ月でした.
主要な成果:
- 臨床的に有意な体重減少は,最初の1年以内にベースラインから20%でした.
- 臨床試験で以前に治療を受けた患者の持続的な体重減少.
- 食欲 (-62%) と食欲 (-41%) を減少させた.
- 3期試験のデータと一致する新しい安全性信号は見つかりませんでした.
結論:
- セトメラノチドは,稀な遺伝的肥満の管理における持続的な臨床的利益を示しています.
- 薬の安全性プロファイルは,以前の試験結果と一致しています.
- これらの結果は,セトメラノチドの長期使用を推奨する.
関連する概念動画
01:16Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253
01:24Obesity
609
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
609
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416